Alvotech And DKSH Extend Partnership For Six Biosimilars
Aim To Target Emerging Asian Markets
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
You may also be interested in...
Hyphens Pharma has struck a licensing deal with DKSH’s Favorex to secure rights to Alvotech’s proposed ustekinumab rival to Stelara in Singapore, Malaysia and the Philippines.
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.